课题基金 / 基金详情

Natural Killer (NK) Cell Immunotherapy Towards Adult T Cell Leukemia (ATL) via Exaltation of MICA/B Expression and Augments NK Cytotoxicity

Natural Killer (NK) Cell Immunotherapy Towards Adult T Cell Leukemia (ATL) via Exaltation of MICA/B Expression and Augments NK Cytotoxicity
通过提高 MICA/B 表达和增强 NK 细胞毒性来治疗成人 T 细胞白血病 (ATL) 的自然杀伤 (NK) 细胞免疫疗法
批准号:
22K16327
负责人:
Panaampon Jutatip
金额:
$2.91万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Early-Career Scientists
财政年份:
2022
资助国家:
日本
项目状态:
已结题
起止时间:
2022-04-01 至 2024-03-31

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
我们检测了不同的ATL细胞系(ED-、TL-OM1、S1T、KK-1、LMHW5、OATL-4和SU9T1)上MICA/B的表达。我们发现ED-OM1和TL-OM1在细胞表面高表达MICA/B,而S1T细胞低表达或不表达MICA/B。我们用ED-,TL-OM1作为代表性的MICA/BHIGH ATL,S1T作为MICA/BNO ATL。然后我们检测了S1T、ED-和TL-OM1对NK细胞的杀伤作用,发现MICA/B表达很低的S1T细胞对NK细胞的杀伤作用具有抵抗力,而ED-和TL-OM1对NK细胞的杀伤作用敏感。结果提示,MICA/B作为NKG2D配体在NK细胞杀伤中起着至关重要的作用。我们检测了IMIDs对MICA/B表达的影响。本研究对来那度胺、泊马度胺、伊贝多胺、CC-92480进行了试验。用ATL法检测非细胞毒性剂量。其中CC-92480对MICA/B基因表达的促进作用最强。使用健康供者的原代NK细胞,我们发现雷那度胺、泊马度胺、伊贝多胺和CC-92480增敏的ATL对NK细胞的杀伤作用最强,其中CC-92480的疗效最高。
英文摘要
We checked MICA/B expression on various ATL cell lines (ED-, TL-Om1, S1T, KK-1, LMHW5, OATL-4, and SU9T1). We found ED- and TL-Om1 express high MICA/B on cell surface whereas S1T cell shows very low/no MICA/B expression. We used ED-, TL-Om1 as representative MICA/Bhigh ATL and S1T as MICA/Bno ATL. We then test S1T, ED-, and TL-Om1 for NK cytotoxicity and found that S1T cells which have very low MICA/B expression, resist to NK cell cytotoxicity whereas ED-, and TL-Om1 are sensitive to NK cytotoxicity. The results suggest that MICA/B, which is NKG2D ligand is crucial for NK cell cytotoxicity.We demonstrate iMIDs increase MICA/B expression on ATL. We tested the efficacy of iMIDs treatment for MICA/B expression. Lenalidomide, Pomalidomide, Iberdomide, CC-92480 were tested in this study. The noncytotoxic doses were tested with ATL. Among all of those, CC-92480 show highest efficacy to enhance MICA/B expression. By using primary NK cells from healthy donor, we found that Lenalidomide, Pomalidomide, Iberdomide and CC-92480 sensitized ATL to NK cytotoxicity and CC-92480 displayed the highest efficacy among iMIDs.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
TKM-011, Anti-CD20 Antibody Confers Multi-Properties Against Burkitt’s Lymphoma in Comparable Efficacy to Rituximab and Obinutuzumab
TKM-011,抗 CD20 抗体具有对抗伯基特淋巴瘤的多种特性,其疗效与利妥昔单抗和 Obinutuzumab 相当
DOI: --
发表时间: 2022
期刊:
影响因子: --
作者: [池田翔, 阿部滉, 北館明宏, 田川博之, 髙橋直人, Jutatip Panaampon and Seiji Okada]
通讯作者: Jutatip Panaampon and Seiji Okada
DOI: 10.21873/anticanres.16259
发表时间: 2023-02
期刊: AntiCancer Research
影响因子: 2
作者: [Ployploen Phikulsod;R. Kariya;Jutatip Panaampon;S. Okada]
通讯作者: Ployploen Phikulsod;R. Kariya;Jutatip Panaampon;S. Okada
Elotuzumab, a potential therapeutic humanized anti-SLAMF7 monoclonal antibody, enhances natural killer cell-mediated killing of primary effusion lymphoma cells
Elotuzumab 是一种潜在的治疗性人源化抗 SLAMF7 单克隆抗体,可增强自然杀伤细胞介导的原发性渗出性淋巴瘤细胞杀伤作用
DOI: 10.1007/s00262-022-03177-6
发表时间: 2022
期刊: Cancer Immunology, Immunotherapy
影响因子: --
作者: [Panaampon Jutatip, Kariya Ryusho, Okada Seiji]
通讯作者: Okada Seiji
海外基金